Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
30 August 2007 - 2:13AM
PR Newswire (US)
ALACHUA, Fla., Aug. 29 /PRNewswire-FirstCall/ -- Tutogen Medical,
Inc. (AMEX:TTG), a leading manufacturer of sterile biological
implant products made from human (allograft) and animal (xenograft)
tissue, announced today that Guy L. Mayer, President and Chief
Executive Officer, will be presenting at the Roth Capital Partners
New York Investor Conference on Thursday, September 6, 2007 at 9:30
a.m. Eastern time. The conference is being held at The Westin NY at
Times Square, 270 West 43rd Street, New York, NY. About Tutogen
Medical, Inc. Tutogen Medical, Inc. manufactures sterile biological
implant products made from human (allograft) and animal (xenograft)
tissue. Tutogen utilizes its proprietary Tutoplast Process(R) of
tissue preservation and viral inactivation to manufacture and
deliver sterile bio-implants used in spinal/trauma, urology,
dental, ophthalmology, and general surgery procedures. The
Company's Tutoplast(R) products are sold and distributed worldwide
by Zimmer Spine and Zimmer Dental, subsidiaries of Zimmer Holdings,
Inc., Davol Inc. subsidiary of C.R. Bard Inc., the Mentor
Corporation (Mentor), Coloplast Corp., IOP, Inc. and through
independent distributors internationally. For more information,
visit the Company's Web site at http://www.tutogen.com/.
Forward-Looking Statement Disclaimer: This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements typically are identified by use of terms such as "may,"
"will," "should," "plan," "expect," "anticipate," "estimate," and
similar words, although some forward-looking statements are
expressed differently. Forward-looking statements are based on
management's current expectations and are subject to certain risks
and uncertainties that could cause actual results to differ
materially from those set forth or implied by forward-looking
statements. These and other risks are identified in the Company's
filings with the Securities and Exchange Commission, including the
Company's Annual Report on Form 10-K for the fiscal year ended
September 30, 2006. All information in this press release is as of
the date hereof, and the Company undertakes no duty to update this
information unless required by law. Contacts: L. Robert Johnston,
Jr. Lytham Partners, LLC Chief Financial Officer Joe Diaz Tutogen
Medical, Inc. Joe Dorame 386-462-0402 Robert Blum 602-889-9700
DATASOURCE: Tutogen Medical, Inc. CONTACT: L. Robert Johnston, Jr.,
Chief Financial Officer of Tutogen Medical, Inc., +1-386-462-0402,
; or Joe Diaz, Joe Dorame or Robert Blum, all of Lytham Partners,
LLC, +1-602-889-9700, for Tutogen Medical, Inc. Web site:
http://www.tutogen.com/
Copyright
Tutogen Medical (AMEX:TTG)
Historical Stock Chart
From Dec 2024 to Jan 2025
Tutogen Medical (AMEX:TTG)
Historical Stock Chart
From Jan 2024 to Jan 2025